<code id='33D821E79B'></code><style id='33D821E79B'></style>
    • <acronym id='33D821E79B'></acronym>
      <center id='33D821E79B'><center id='33D821E79B'><tfoot id='33D821E79B'></tfoot></center><abbr id='33D821E79B'><dir id='33D821E79B'><tfoot id='33D821E79B'></tfoot><noframes id='33D821E79B'>

    • <optgroup id='33D821E79B'><strike id='33D821E79B'><sup id='33D821E79B'></sup></strike><code id='33D821E79B'></code></optgroup>
        1. <b id='33D821E79B'><label id='33D821E79B'><select id='33D821E79B'><dt id='33D821E79B'><span id='33D821E79B'></span></dt></select></label></b><u id='33D821E79B'></u>
          <i id='33D821E79B'><strike id='33D821E79B'><tt id='33D821E79B'><pre id='33D821E79B'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:928

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Will General Catalyst be the first of many hospital takeovers?
          Will General Catalyst be the first of many hospital takeovers?

          AdobeGeneralCatalyst’splantotakeoverahospitalinthecomingmonthscouldbethefirstofmanysuchdeals,drivenb

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          FDA approves potent Eli Lilly obesity drug, Zepbound

          DarronCummings/APEliLilly’sblockbusterdrugtirzepatide,soldasMounjarofortype2diabetes,hasbeenclearedt